BEAM
Beam Therapeutics IncNASDAQHEALTHCAREBIOTECHNOLOGY
Key Statistics
Market Cap
$2.47B
P/E Ratio
—
EPS
$-0.81
Beta
2.19
52W High
$36.44
52W Low
$13.54
50-Day MA
$26.71
200-Day MA
$24.04
Dividend Yield
—
Profit Margin
-57.20%
Forward P/E
—
PEG Ratio
—
About Beam Therapeutics Inc
Beam Therapeutics Inc., a biotechnology company, develops precision genetic drugs for patients with serious illnesses in the United States. The company is headquartered in Cambridge, Massachusetts.
Fundamentals
| Revenue (TTM) | $139.74M |
| Gross Profit (TTM) | $-269.88M |
| EBITDA | $-361.40M |
| Operating Margin | -15.30% |
| Return on Equity | -8.11% |
| Return on Assets | -18.50% |
| Revenue/Share (TTM) | $1.41 |
| Book Value | $12.48 |
| Price-to-Book | 2.03 |
| Price-to-Sales (TTM) | 17.66 |
| EV/Revenue | 10.17 |
| EV/EBITDA | -7.03 |
| Quarterly Earnings Growth (YoY) | 0.00% |
| Quarterly Revenue Growth (YoY) | 279.50% |
| Shares Outstanding | $101.86M |
| Float | $88.04M |
| % Insiders | 1.23% |
| % Institutions | 104.68% |
Analyst Ratings
Consensus ($51.20 target)
1
Strong Buy14
Buy2
HoldData last updated: 4/7/2026